Keyword Analysis & Research: trillium therapeutics
Keyword Research: People who searched trillium therapeutics also searched
Search Results related to trillium therapeutics on Search Engine
-
Pfizer Completes Acquisition of Trillium Therapeutics
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics
WEBNov 17, 2021 · NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for …
DA: 45 PA: 79 MOZ Rank: 50
-
Pfizer to Acquire Trillium Therapeutics Inc. | Pfizer
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-trillium-therapeutics-inc
WEBAug 23, 2021 · NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for …
DA: 27 PA: 78 MOZ Rank: 96
-
Trillium Therapeutics Shares Soar Over 40% on $25 Million Pfizer
https://finance.yahoo.com/news/trillium-therapeutics-shares-soar-over-054338300.html
WEBSep 9, 2020 · Trillium Therapeutics’ shares jumped over 40% to $13.37 in after-hours trading. Also, the stock is up over 800% so far this year after closing at $1.03 in 2019.
DA: 20 PA: 53 MOZ Rank: 31
-
Pfizer Acquires Trillium, Gains Anti-CD47 Assets
https://aacrjournals.org/cancerdiscovery/article/11/11/2666/666437/Pfizer-Acquires-Trillium-Gains-Anti-CD47
WEBNov 1, 2021 · Pfizer is paying $2.26 billion to acquire Trillium Therapeutics, maker of two clinical-stage fusion proteins directed against CD47, the “do not eat me” signal that cancer cells co-opt to shield themselves from macrophage-mediated killing.
DA: 28 PA: 95 MOZ Rank: 26
-
Pfizer to buy cancer drug developer Trillium in $2.3 bln deal
https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/
WEBAug 23 (Reuters) - Pfizer Inc (PFE.N) said on Monday it would buy Canadian drug developer Trillium Therapeutics Inc (TRIL.TO) in a $2.26 billion deal to strengthen its arsenal of blood cancer ...
DA: 63 PA: 63 MOZ Rank: 7
-
Pfizer to buy oncology biotech in $2.3bn deal - Financial Times
https://www.ft.com/content/d673c756-eb4c-45e1-822d-b520158768c6
WEBAug 23, 2021 · Pfizer to buy oncology biotech in $2.3bn deal. US drugmaker to buy all shares of Trillium Therapeutics as part of investment in blood cancers. Blood cancers make up about 6 per cent of all cancers ...
DA: 82 PA: 12 MOZ Rank: 53
-
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion - Yahoo Finance
https://finance.yahoo.com/news/trillium-tril-acquired-pfizer-2-160304451.html
WEBAug 24, 2021 · Zacks Equity Research. August 24, 2021 · 2 min read. Trillium Therapeutics Inc. TRIL entered into a definitive agreement with pharma giant Pfizer PFE, whereby it will be acquired by the latter ...
DA: 13 PA: 48 MOZ Rank: 91
-
UPDATE: Pfizer and Trillium: How a $25M investment led to a …
https://www.fiercebiotech.com/biotech/pfizer-and-trillium-how-a-25m-investment-led-to-a-2-3b-buyout
WEBSep 14, 2021 · Pfizer was in a hurry to seal its takeover of cancer startup Trillium Therapeutics, a relationship that was first sparked after the Big Pharma spied some early clinical data at the American Society.
DA: 58 PA: 45 MOZ Rank: 16
-
Trillium Therapeutics Provides Data Update, Announces Phase
https://www.globenewswire.com/news-release/2021/04/28/2218460/33016/en/Trillium-Therapeutics-Provides-Data-Update-Announces-Phase-1b-2-Program-Priorities-Across-Hematologic-Malignancies-and-Solid-Tumors-and-Reports-Governance-Changes.html
WEBApril 28, 2021 07:00 ET | Source: Trillium Therapeutics Inc. Follow. TTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses ...
DA: 99 PA: 23 MOZ Rank: 52
-
Trillium Therapeutics Announces Dosing of First Patient in
https://www.globenewswire.com/news-release/2021/07/06/2258077/33016/en/Trillium-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1b-2-Study-of-TTI-622-in-Combination-With-Azacitidine-and-Venetoclax-in-TP53-Wild-Type-Acute-Myeloid-Leukemia.html
WEBJul 6, 2021 · Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia. July 06, 2021 07:00...
DA: 30 PA: 9 MOZ Rank: 94